Initial Treatment for Climacteric Menorrhagia

Assessment and Diagnosis

The initial assessment should rule out underlying health conditions that may cause heavy bleeding, including medication interactions, sexually transmitted infections, pregnancy, thyroid disorders, and pathologic uterine conditions (polyps or fibroids) 1, 2, 3
It is essential to determine if the bleeding pattern is heavy or prolonged bleeding, or if it follows a regular or irregular pattern 1, 3, 4

The American College of Obstetricians and Gynecologists recommends nonsteroidal anti-inflammatory drugs (NSAIDs) for 5-7 days during bleeding episodes as the first-line treatment for climacteric menorrhagia 1, 2, 4
Options for NSAIDs include ibuprofen, mefenamic acid, or celecoxib, which reduce prostaglandin levels in the endometrium 1

For women with severe thrombocytopenia, progestin-only contraceptives might be useful in treating menorrhagia, but DMPA should be used with caution due to its irreversibility for 11-13 weeks after administration 5, 6, 7

Failing to rule out underlying pathology before initiating treatment can lead to ineffective or delayed treatment, and the Centers for Disease Control and Prevention recommends a thorough assessment before starting any therapy 1, 2
Not providing adequate counseling about expected changes in bleeding patterns with hormonal treatments can lead to patient non-adherence, and the American College of Obstetricians and Gynecologists recommends thorough patient education 4